Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H23N5O5 |
Molecular Weight | 449.4592 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(N)=C2C=C(CCC3=CC=C(C=C3)C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=CC2=N1
InChI
InChIKey=NAWXUBYGYWOOIX-SFHVURJKSA-N
InChI=1S/C23H23N5O5/c1-12(21(30)31)10-18(22(32)33)26-20(29)15-7-4-13(5-8-15)2-3-14-6-9-17-16(11-14)19(24)28-23(25)27-17/h4-9,11,18H,1-3,10H2,(H,26,29)(H,30,31)(H,32,33)(H4,24,25,27,28)/t18-/m0/s1
Molecular Formula | C23H23N5O5 |
Molecular Weight | 449.4592 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:43:53 GMT 2023
by
admin
on
Sat Dec 16 17:43:53 GMT 2023
|
Record UNII |
86T288K8BS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11532464
Created by
admin on Sat Dec 16 17:43:53 GMT 2023 , Edited by admin on Sat Dec 16 17:43:53 GMT 2023
|
PRIMARY | |||
|
86T288K8BS
Created by
admin on Sat Dec 16 17:43:53 GMT 2023 , Edited by admin on Sat Dec 16 17:43:53 GMT 2023
|
PRIMARY | |||
|
227016-66-2
Created by
admin on Sat Dec 16 17:43:53 GMT 2023 , Edited by admin on Sat Dec 16 17:43:53 GMT 2023
|
PRIMARY | |||
|
300000047882
Created by
admin on Sat Dec 16 17:43:53 GMT 2023 , Edited by admin on Sat Dec 16 17:43:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Alternative Names: CH-4051, L-CH-1504; Originator: University of South Alabama; Developer: Lundbeck A/S; Class: Anti-inflammatory; Mechanism of Action: Tetrahydrofolate dehydrogenase inhibitor; Highest Development Phases: Suspended for Autoimmune disorders, Rheumatoid arthritis; Most Recent Events: 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S, 31 May 2012 Suspended - Phase-I for Autoimmune disorders (in volunteers) in Netherlands (PO), 31 May 2012 Suspended - Phase-II for Rheumatoid arthritis (treatment-resistant) in Czech Republic (PO)
|